我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Researchers at Sidney Kimmel Cancer Center are developing an innovative anti-MDM2 PROTAC therapy that targets p73 activation to induce cancer cell death in p53-mutated tumors. - The experimental treatment works by degrading MDM2 proteins, triggering cellular stress that activates p73, which shares transcriptional targets with p53 and can promote apoptosis. - The research team, led by Dr. Christine M. Eischen, is currently optimizing the MDM2 PROTAC compound before advancing to clinical trials with cancer patients.
